Lovelace Biomedical Receives FDA Warning Letter Over GLP Raw Data Reconciliation Failures

Raw data reconciliation failures at Lovelace Biomedical Research Institute (LBRI) have drawn a formal FDA Warning Letter, signaling that quality assurance unit oversight of nonclinical study reports remains a live inspection risk for CROs and the sponsors who rely on their data packages. The letter, issued October 6, 2026, and referencing an April 2025 Bioresearch Monitoring Program inspection, identifies systemic gaps between documented observations and final study report content across two nonclinical GLP protocols.

Under 21 CFR 58.35(b)(6), the QAU is required to verify that final study reports accurately reflect underlying raw data. At LBRI, that obligation was not met. For one protocol, 20 of 34 animals had abnormal cageside clinical observations, including bloody nasal discharge, hunched posture, and labored breathing recorded between October 2023 and January 2024, that were absent from the final report. Dosing incidents were similarly omitted: one animal remained recumbent for over an hour post-infusion; two others dislodged venous catheters during test article administration; a fourth experienced extravasation into tissue surrounding the left saphenous vein.

A second protocol compounded the picture. Abnormal stool observations across all 48 animals, documented over an eight-month window from November 2022 through July 2023, were not carried through to the final study report. The pattern across both protocols points to a QAU review process that did not systematically cross-reference raw data forms against draft and final report narratives before sign-off.

For QA directors and regulatory affairs leads at sponsor organizations, the inspection record carries a direct implication: study data submitted to CDER in support of an IND or NDA is only as defensible as the CRO's QAU controls. FDA's Bioresearch Monitoring Program is designed precisely to surface this gap, and a Warning Letter at the testing facility level can trigger data integrity questions that reach back to the sponsor's own regulatory submissions. Contractual QAU oversight provisions and pre-submission raw data audits are the practical controls most directly implicated here.

LBRI submitted a written response to the Form FDA 483 on May 9, 2025; FDA's review of that response, alongside the Establishment Inspection Report, concluded the corrective commitments did not resolve the cited deficiencies, a finding that escalated the matter to Warning Letter status more than a year after the inspection closed.

The adequacy of LBRI's corrective action plan, and whether FDA requires a follow-up inspection before accepting data from the facility, will determine the downstream impact on any pending submissions that reference the affected protocols.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Warning Letters, October 13, 2026.